Did the approval of lutetium Lu 177 vipivotide tetraxetan (Pluvicto) change how you image and manage patients with metastatic castrate-resistant prostate cancer?

The FDA approval of Pluvicto was a welcome addition to a growing list of treatments for patients with mCRPC. Logistical issues with administration have slowed the routine implementation of this therapy in the US. In terms of imaging, a PSMA-PET is required prior to the administration of Pluvicto to ...